Biopharmaceutical R&D and commercialization with global manufacturing and clinical operations
Regeneron operates a large-scale biopharmaceutical development and manufacturing engine built on life sciences software (Epic, Veeva, LIMS, JMP, SAS) paired with analytics stacks (Python, R, SQL, scikit-learn, Tableau, Power BI). The hiring profile is clinical and research-heavy (research 118 roles, healthcare 76, senior/director bias), while active projects span late-stage clinical trials (obesity, respiratory, multiple myeloma), market access strategy, and Oracle ERP migration — indicating a shift toward financial and procurement automation as the company scales commercialization. Pain-point clustering around GMP/GXP compliance, data integrity, and reimbursement access signals friction in regulated drug development and market entry.
Notable leadership hires: Clinical Study Lead, Medical Director, Imaging Scientific Director, Director Insights, Medical Affairs Lead
Regeneron is a publicly traded biopharmaceutical company headquartered in Tarrytown, New York, with 10,000+ employees across the United States, United Kingdom, Japan, Ireland, Netherlands, Germany, and other countries. The company invents, develops, and commercializes medicines for serious diseases, operating integrated R&D, clinical, manufacturing, and commercial functions. Core operational systems include Epic for clinical/healthcare workflows, Veeva for life sciences data management, LIMS for lab operations, and analytical tools (JMP, SAS, Python, R) embedded in research and manufacturing processes. Active infrastructure modernization includes migration from Oracle EBS to Oracle Fusion Cloud Financials and adoption of ITIL frameworks.
Life sciences (Epic, Veeva, LIMS, JMP, SAS), analytics (Python, R, SQL, scikit-learn, Tableau, Power BI), ERP (Workday, ServiceNow, Oracle), and laboratory instruments (HPLC). Currently migrating to Oracle Fusion Cloud Financials from Oracle EBS.
Active pipeline includes multiple myeloma and obesity medicines in clinical development, plus respiratory clinical trials (post-approval interventional and non-interventional). Territory and market access strategy development is underway across multiple therapeutic areas.
Other companies in the same industry, closest in size